Cancer Genetics, Inc., (CGI) has announced that it has received CLIA and New York state approvals for clinical use of its proprietary mature B-cell neoplasm array, or MatBA, for Follicular Lymphoma (MatBA-FL) and Mantle-Cell Lymphoma (MatBA-MCL). Both tests further extend the portfolio in hematologic cancers being developed by CGI, and both were developed and validated via research collaboration with Memorial Sloan-Kettering Cancer Center. MatBA-FL identifies genomic aberrations that are associated with the high frequency of transformation of FL into diffuse large B-cell lymphoma (DLBCL) and shorter overall survival (OS). MatBA-MCL identifies genomic aberrations that are associated with high frequency of either a leukemic involvement and/or shorter OS.
CGI’s MatBA platform has been designed to detect chromosomal gains and losses at more than 80 specific genomic sites associated with mature B-cell neoplasms. MatBA is designed for use in a clinical laboratory and is optimized for use on a range of specimen types such as peripheral blood, bone marrow, cell suspension, and formalin-fixed paraffin-embedded tissue specimens. According to CGI spokespersons, MatBA may improve patients' prognoses by determining each patient’s unique genetic profile, allowing doctors to more accurately select treatments to which the patient is most likely to respond. No time is wasted with treatment that will not work, which is vital for many cancers requiring immediate therapy.
The MatBA-FL and MatBA-MCL join the Diffuse Large B-Cell Lymphoma (DLBCL) Complete Program offered by CGI, which includes a suite of esoteric tests used in the diagnosis, prognosis, and clinical management of DLBCL patients. Read more about the MatBA product line.Read more